Dr Reddy's Laboratories rose 3.56% to Rs 2,302.30 at 12:09 IST on BSE after the company announced that it received an approval from the US drug regulator for Azacitidine for injection.
The announcement was made during trading hours today, 17 September 2013.
Meanwhile, the BSE Sensex was almost flat at 19,743.31
On BSE, 12,000 shares were traded in the counter compared with average volume of 21,202 shares in the past one quarter.
The stock hit a high of Rs 2,311.50 and a low of Rs 2,220 so far during the day. The stock hit a record high of Rs 2,400.75 on 15 July 2013. The stock hit a 52-week low of Rs 1,617 on 27 September 2012.
The stock had underperformed the market over the past one month till 16 September 2013, rising 2.60% compared with the Sensex's 6.15% rise. The scrip had also underperformed the market in past one quarter, falling 2.14% as against Sensex's 2.94% rise.
The large-cap company has an equity capital of Rs 85.05 crore. Face value per share is Rs 5.
Dr Reddys Laboratories announced that Azacitidine for injection 100 milligram (mg)/vial, a bioequivalent generic version of VIDAZA, was approved by the US Food and Drug Administration (US FDA) on 16 September 2013. The launch of the product in the market is planned in the near term, the company said.
The VIDAZA brand had US sales of approximately $378.5 million for the most recent twelve months ending July 2013 according to IMS health. The drug is used for the treatment of patients with myelodysplastic syndromes.
Dr Reddys Laboratories said that Azacitidine for injection 100 mg/vial is available in single use vials.
On a consolidated basis, Dr Reddy's Laboratories' net profit rose 7.43% to Rs 360.93 crore on 12% increase in net sales to Rs 2844.92 crore in Q1 June 2013 over Q1 June 2012.
Dr. Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including active pharmaceutical ingredients (APIs), custom pharmaceutical services, generics, biosimilars, differentiated formulations and new chemical entities (NCEs).
Powered by Capital Market - Live News
